Erenumab for preventing migraine -guidance (TA682)

NICE recommends erenumab for preventing migraine in adults, only if they have 4 or more migraine days/month, at least 3 preventive drug treatments have failed, and the 140 mg dose is used.

SPS commentary:

Treatment should be stopped after 12 weeks in episodic migraine (<15 headache days/month) if the frequency does not reduce by 50%, and in chronic migraine (>15 headache days/month, at least 8 of which are migraine days) if the frequency does not reduce by 30%.

National Institute for Health and Care Excellence